Voltaren-XR is a brand name of diclofenac, approved by the FDA in the following formulation(s):
VOLTAREN-XR (diclofenac sodium - tablet, extended release; oral)
Manufacturer: NOVARTIS
Approval date: March 8, 1996
Strength(s): 100MG [RLD][AB]
Has a generic version of Voltaren-XR been approved?
Yes. The following products are equivalent to Voltaren-XR:
diclofenac sodium tablet, extended release; oral
Manufacturer: ACTAVIS ELIZABETH
Approval date: January 7, 2002
Strength(s): 100MG [AB]
Manufacturer: DEXCEL LTD
Approval date: November 6, 2002
Strength(s): 100MG [AB]
Manufacturer: MYLAN
Approval date: December 13, 2001
Strength(s): 100MG [AB]
Manufacturer: VALEANT INTL
Approval date: February 11, 2000
Strength(s): 100MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Voltaren-XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
There are no current U.S. patents associated with Voltaren-XR.
See also...
- Voltaren XR Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Voltaren-XR Consumer Information (Cerner Multum)
- Voltaren-XR Advanced Consumer Information (Micromedex)
- Diclofenac Consumer Information (Drugs.com)
- Diclofenac Consumer Information (Wolters Kluwer)
- Diclofenac Enteric-Coated Tablets Consumer Information (Wolters Kluwer)
- Diclofenac Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Diclofenac Immediate-Release Tablets Consumer Information (Wolters Kluwer)
- Diclofenac Potassium Powder Packets Consumer Information (Wolters Kluwer)
- Diclofenac Consumer Information (Cerner Multum)
- Diclofenac Advanced Consumer Information (Micromedex)
- Diclofenac Potassium AHFS DI Monographs (ASHP)
- Diclofenac Sodium AHFS DI Monographs (ASHP)
- Diclofenac epolamine AHFS DI Monographs (ASHP)
No comments:
Post a Comment